Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 9/20 | 0.45 |
| ▸ | PPARG | P37231 | 8/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4334192 | 0.91 | MGLL (0.60) | MGLLPPARAPPARGSLC1A3SLC1A2 | |
| SCHEMBL4329822 | 0.91 | MGLL (0.53) | MGLLPPARAPPARGSLC1A3SLC1A2 | |
| SCHEMBL4329894 | 0.90 | MGLL (0.49) | MGLLFPR2PPARAPPARGSLC1A3 | |
| SCHEMBL4341815 | 0.90 | FPR2 (0.45) | MGLLFPR2PPARAPPARGPPARD | |
| SCHEMBL4347142 | 0.90 | MEN1 (0.52) | MGLLFPR2PPARAPPARGPPARD | |
| SCHEMBL4334181 | 0.90 | MEN1 (0.52) | MGLLFPR2PPARAPPARGPPARD | |
| SCHEMBL4340027 | 0.89 | MGLL (0.53) | MGLLPPARAPPARGSLC1A3SLC1A2 | |
| SCHEMBL4328906 | 0.88 | MGLL (0.52) | MGLLMEN1KMT2APOLB | |
| SCHEMBL4339291 | 0.88 | MEN1 (0.50) | MGLLPPARAPPARGPPARDMEN1 | |
| SCHEMBL4348594 | 0.87 | MEN1 (0.49) | MGLLPPARAPPARGMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | MGLL 3539/4885FPR2 632/4885PPARA 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.